Troy is the chief scientific officer at Verve Therapeutics. He has more than 15 years of experience in the biopharmaceutical industry, with extensive work in drug discovery, research, and development and program and portfolio leadership. Prior to joining Verve, he served as senior vice president of research and development at Spero Therapeutics, where he helped build the research and development organization and led multiple programs into first-in-human studies and through early clinical development. Previously, Troy held scientific and leadership roles at the Novartis Institutes for Biomedical Research and AstraZeneca. 

Troy holds a B.Sc. and Ph.D. in Organic Chemistry from Flinders University, Australia. He completed post-doctoral studies in bioactive natural product total synthesis at The Scripps Research Institute with Professor K.C. Nicolaou.